When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Ted Tent ...

New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its ... comprises the Phase II ...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...